OKYO צמיחה צפויה ברווח נקי למניה השנה OKYO Pharma Limited

OKYO Pharma Limited is developing advanced eye drops to combat dry eye by targeting the neural mechanisms of inflammation. The company focuses on ophthalmology centers, utilizing non-peptide antagonists for corneal therapy. The current pipeline is centered on preparing critical Phase II trial data. The year-over-year percentage change in EPS demonstrates a pivot, and the value of 20.90 reflects this status of the issuer's financial dynamics.
פילוחים אנליטיים ודוחות נתונים של חברת okyopharma.com (OKYO)

Investors assess the financial stability of the issuer through earnings per share dynamics. This indicator calculates the percentage deviation of the current EPS from the previous year's value, measuring the speed of capital recovery. For OKYO Pharma (OKYO), whose ophthalmological developments are independent of market cycles, this parameter reflects pure scientific progress. The annual EPS growth trend allows for the verification of the business recovery pace. Analyzing this trajectory eliminates the risk of overpaying for unconfirmed successes.